<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39135572</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-7778</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Transactions of the American Clinical and Climatological Association</Title><ISOAbbreviation>Trans Am Clin Climatol Assoc</ISOAbbreviation></Journal><ArticleTitle>A MULTI-HIT MODEL OF LONG COVID PATHOPHYSIOLOGY: THE INTERACTION BETWEEN IMMUNE TRIGGERS AND NERVOUS SYSTEM SIGNALING.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>164</EndPage><MedlinePgn>149-164</MedlinePgn></Pagination><Abstract><AbstractText>Early in the pandemic, clinicians recognized an overlap between Long COVID symptoms and dysautonomia, suggesting autonomic nervous system (ANS) dysfunction. Our clinical experience at Johns Hopkins with primary dysautonomia suggested heritability of sympathetic dysfunction, manifesting primarily as hyperhidrosis and as other dysautonomia symptoms. Whole exome sequencing revealed mutations in genes regulating electrical signaling in the nervous system, thus providing a genetic basis for the sympathetic overdrive observed. We hypothesize that dysautonomia in Long COVID requires two molecular hits: a genetic vulnerability to prime the ANS and a SARS-CoV-2 infection, as an immune trigger, to further disrupt ANS function resulting in increased sympathetic activity. Indeed, Long COVID patients show signs of chronic inflammation and autoimmunity. We have translated this two-hit concept to the clinic using ion channel inhibitors to target genetic susceptibility and immunomodulators to treat inflammation. This multi-hit hypothesis shows promise for managing Long COVID and merits further study.</AbstractText><CopyrightInformation>&#xa9; 2024 The American Clinical and Climatological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Malcolm V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosmans</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Trans Am Clin Climatol Assoc</MedlineTA><NlmUniqueID>7507559</NlmUniqueID><ISSNLinking>0065-7778</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054969" MajorTopicYN="N">Primary Dysautonomias</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39135572</ArticleId><ArticleId IdType="pmc">PMC11316875</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Worldometer. COVID-19 Coronavirus Pandemic. 2023.   https://www.worldometers.info/coronavirus/November, 24, 2023.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. E Clin Med . 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Perego@elisaperego78, E. Twitter. 2020.   https://twitter.com/elisaperego78/status/1263172084055838721?s=20 November, 24, 2023.</Citation></Reference><Reference><Citation>Danesh V, Arroliga AC, Bourgeois JA. Symptom clusters seen in adult COVID-19 recovery clinic care seekers. J Gen Intern Med . 2023;38(2):442&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9663188</ArticleId><ArticleId IdType="pubmed">36376627</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine . 2023;87:104413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet . 2021;397(10270):220&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>thebmjopinion. Why We Need to Keep Using the Patient Made Term &#x201c;Long COVID.&#x201d; 2021.   https://blogs.bmj.com/bmj/2020/10/01/why-we-need-to-keep-using-the-patient-made-term-long-covid/, November 24 2023.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol . 2023;21(3):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A. Long COVID: What Do the Latest Data Show? 2023.   https://www.kff.org/policy-watch/long-covid-what-do-latest-data-show/; November 24 2023.</Citation></Reference><Reference><Citation>Nittas V, Gao M, West EA. Long COVID through a public health lens: an umbrella review. Public Health Rev . 2022;43:1604501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8963488</ArticleId><ArticleId IdType="pubmed">35359614</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M. Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw Open . 2021;4(10):e2130645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Yang D, Lewis A. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. J Neurol Sci . 2021;426:117486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113108</ArticleId><ArticleId IdType="pubmed">34000678</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention C.f.D.C.a. Long COVID in Adults: United States. 2022.   https://www.cdc.gov/nchs/products/databriefs/db480.htm; November 24 2023.</Citation></Reference><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG. The epidemiology of long coronavirus disease in US adults. Clin Infect Dis . 2023;76(9):1636&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect . 2022;28(4):611 e9&#x2013;611. e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Census Bureau. U.S.C. Hispanic, Black Adults More Likely to Report Long COVID-19 Symptoms. 2023.   https://www.census.gov/library/stories/2023/05/long-covid-19-symptoms-reported.html November 24 2023.</Citation></Reference><Reference><Citation>Burns A. What Are the Implications of Long COVID for Employment and Health Coverage? 2022.   https://www.kff.org/policy-watch/what-are-the-implications-of-long-covid-for-employment-and-health-coverage/#:~:text=Two%20surveys%20of%20people%20with,7%25%20were%20out%20of%20work November 24 2023.</Citation></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry . 2021;8(5):416&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum . 2022;3(5):e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz GM, Bach K, Bobos P. Understanding how post-COVID-19 condition affects adults and health care systems. JAMA Health Forum . 2023;4(7):e231933.</Citation><ArticleIdList><ArticleId IdType="pubmed">37418268</ArticleId></ArticleIdList></Reference><Reference><Citation>Koumpias AM, Schwartzman D, Fleming O. Long-haul COVID: healthcare utilization and medical expenditures 6 months post-diagnosis. BMC Health Serv Res . 2022;22(1):1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9358916</ArticleId><ArticleId IdType="pubmed">35941617</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein DS. The extended autonomic system, dyshomeostasis, and COVID-19. Clin Auton Res . 2020;30(4):299&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7374073</ArticleId><ArticleId IdType="pubmed">32700055</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein DS. The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm . 2021;18(4):508&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7729277</ArticleId><ArticleId IdType="pubmed">33316414</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P. Autonomic dysfunction in &#x201c;long COVID&#x201d;: rationale, physiology and management strategies. Clin Med (Lond) 2021;21(1): e63&#x2013;e67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Barizien N, Le Guen M, Russel S. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep . 2021;11(1):14042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8263555</ArticleId><ArticleId IdType="pubmed">34234251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadda KR, Blakey EE, Huang CL. Long COVID-19 and postural orthostatic tachycardia syndrome&#x2014;is dysautonomia to be blamed? Front Cardiovasc Med . 2022;9:860198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8959615</ArticleId><ArticleId IdType="pubmed">35355961</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldokla AM, Mohamed-Hussein AA, Fouad AM. Prevalence and patterns of symptoms of dysautonomia in patients with long-COVID syndrome: a cross-sectional study. Ann Clin Transl Neurol . 2022;9(6):778&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110879</ArticleId><ArticleId IdType="pubmed">35393771</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona-Torre F, Minguez-Olaondo A, Lopez-Bravo A. Dysautonomia in COVID-19 patients: a narrative review on clinical course, diagnostic and therapeutic strategies. Front Neurol . 2022;13:886609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9198643</ArticleId><ArticleId IdType="pubmed">35720084</ArticleId></ArticleIdList></Reference><Reference><Citation>Shouman K, Vanichkachorn G, Cheshire WP. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res . 2021;31(3):385&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050227</ArticleId><ArticleId IdType="pubmed">33860871</ArticleId></ArticleIdList></Reference><Reference><Citation>Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res . 2021;69(2):205&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009458</ArticleId><ArticleId IdType="pubmed">33786700</ArticleId></ArticleIdList></Reference><Reference><Citation>Varella AY, Fukuda JM, Teivelis MP. Translation and validation of hyperhidrosis disease severity scale. Rev Assoc Med Bras (1992) 2016;62(9):843&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28001258</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassallo M, Camilleri M, Caron BL. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology . 1991;100(1):252&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1983829</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohlgeers KM, Stumbo JR. Syncope in an athlete: a case of infectious mononucleosis-induced postural tachycardia syndrome. Curr Sports Med Rep . 2016;15(1):41&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">26745170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ejima M, Ota K, Yamamoto K. A case of acute pandysautonomia and diffuse brain stem impairment associated with EB virus infection. Rinsho Shinkeigaku . 1994;34(11):1136&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">7729095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjwal K, Karabin B, Kanjwal Y. Postural orthostatic tachycardia syndrome following Lyme disease. Cardiol J . 2011;18(1):63&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21305487</ArticleId></ArticleIdList></Reference><Reference><Citation>Noyes AM, Kluger J. A tale of two syndromes: Lyme disease preceding postural orthostatic tachycardia syndrome. Ann Noninvasive Electrocardiol . 2015;20(1):82&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6931862</ArticleId><ArticleId IdType="pubmed">24830783</ArticleId></ArticleIdList></Reference><Reference><Citation>Burman M, Nguyen HL, Murthy V. Severe orthostatic hypotension in a diabetic patient may not be due to diabetic autonomic neuropathy. Clin Med (Lond) 2011;11(3):290&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4953329</ArticleId><ArticleId IdType="pubmed">21902089</ArticleId></ArticleIdList></Reference><Reference><Citation>Gila L, Guerrero A, Astarloa R. Reflex sympathetic dystrophy. A new manifestation of Lyme disease? Enferm Infecc Microbiol Clin . 1990;8(1):32&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2095902</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler T, Weber DM. On the nature of orthostatic hypotension in acute malaria. Am J Trop Med Hyg . 1973;22(4):439&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">4577812</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakorn C, Wilairatana P, Krudsood S. Severe orthostatic hypotension in otherwise uncomplicated Plasmodium vivax infection. Malar J . 2021;20(1):28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792005</ArticleId><ArticleId IdType="pubmed">33413379</ArticleId></ArticleIdList></Reference><Reference><Citation>Touradji P, Aucott JN, Yang T. Cognitive decline in post-treatment Lyme disease syndrome. Arch Clin Neuropsychol . 2019;34(4):455&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">29945190</ArticleId></ArticleIdList></Reference><Reference><Citation>Garakani A, Mitton AG. New-onset panic, depression with suicidal thoughts, and somatic symptoms in a patient with a history of lyme disease. Case Rep Psychiatry . 2015:457947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4397473</ArticleId><ArticleId IdType="pubmed">25922779</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagundes CP, Jaremka LM, Glaser R. Attachment anxiety is related to Epstein-Barr virus latency. Brain Behav Immun . 2014;41:232&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4304069</ArticleId><ArticleId IdType="pubmed">24945717</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa-Goncalves P, Ribeiro-Gomes FL, Daniel-Ribeiro CT. Malaria related neurocognitive deficits and behavioral alterations. Front Cell Infect Microbiol . 2022;12:829413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8904205</ArticleId><ArticleId IdType="pubmed">35281436</ArticleId></ArticleIdList></Reference><Reference><Citation>Brock M, Chung TH, Gaddam SR. Resolution of postural orthostatic tachycardia syndrome after CT-guided, percutaneous T2 ethanol ablation for hyperhidrosis. Cardiovasc Intervent Radiol . 2016;39(12):1785&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27558116</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Rhermoul FZ, Fedorowski A, Eardley P. Autoimmunity in long Covid and POTS. Oxf Open Immunol . 2023;4(1):iqad002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10224806</ArticleId><ArticleId IdType="pubmed">37255928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallick D, Goyal L, Chourasia P. COVID-19 induced postural orthostatic tachycardia syndrome (POTS): a review. Cureus . 2023;15(3):e36955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10065129</ArticleId><ArticleId IdType="pubmed">37009342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormiston CK, Swiatkiewicz I, Taub PR. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm . 2022;19(11):1880&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9287587</ArticleId><ArticleId IdType="pubmed">35853576</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley MC, Gallagher C, Ong E. High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long COVID: implications for management and health care planning. Am J Med . 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10307671</ArticleId><ArticleId IdType="pubmed">37391116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez B, Hoepner R, Salmen A. Immunomodulatory treatment in postural tachycardia syndrome: a case series. Eur J Neurol . 2021;28(5):1692&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33382525</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitarokoili K, Maier A, de Moya Rubio EC. Maintenance therapy with subcutaneous immunoglobulin in a patient with immune-mediated neuropathic postural tachycardia syndrome. J Transl Autoimmun . 2021;4:100112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387908</ArticleId><ArticleId IdType="pubmed">34471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Schofield JR, Chemali KR. Intravenous immunoglobulin therapy in refractory autoimmune dysautonomias: a retrospective analysis of 38 patients. Am J Ther . 2019;26(5):570&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">29781817</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin . 2014;32(4):467&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">25152339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornberger J, Grimes K, Naumann M. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol . 2004;51(2):274&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">15280848</ArticleId></ArticleIdList></Reference><Reference><Citation>Cina CS, Clase CM. The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res . 1999;8(8):693&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10855343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetindag IB, Boley TM, Webb KN. Long-term results and quality-of-life measures in the management of hyperhidrosis. Thoracic Surgery Clinics . 2008;18(2):217&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18557594</ArticleId></ArticleIdList></Reference><Reference><Citation>Li DC, Hulbert A, Waldbaum B. Endoscopic thoracic sympathectomy for primary focal hyperhidrosis: impact on psycho-social symptomatology and psychotropic medication use. Eur J Cardiothorac Surg . 2018;54(5):904&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454516</ArticleId><ArticleId IdType="pubmed">29860276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K, Kang WH, Saga K. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol . 1989;20(5 Pt 1):713&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2654213</ArticleId></ArticleIdList></Reference><Reference><Citation>Engels W., Wittkower E. In: Allergic and Skin Disorders. Comprehensive Textbook of Psychiatry . Freedman A. M., Kaplan H. I., editors. 1095. Baltimore, MD: Williams &amp; Wilkins; 1967.</Citation></Reference><Reference><Citation>Chalmers TM, Keele CA. The nervous and chemical control of sweating. Br J Dermatol . 1952;64(2):43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">14904842</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up. J Am Acad Dermatol . 2019;81(3):657&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">30710604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lear W, Kessler E, Solish N. An epidemiological study of hyperhidrosis. Dermatologic Surgery . 2007;33:S69&#x2013;S75.</Citation><ArticleIdList><ArticleId IdType="pubmed">17241417</ArticleId></ArticleIdList></Reference><Reference><Citation>Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol . 2009;61(2):242&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19395123</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler BL, Russell JW, Hummers LK. Symptoms of autonomic dysfunction in systemic sclerosis assessed by the COMPASS-31 questionnaire. J Rheumatol . 2018;45(8):1145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6072589</ArticleId><ArticleId IdType="pubmed">29907667</ArticleId></ArticleIdList></Reference><Reference><Citation>Treister R, O&#x2019;Neil K, Downs HM. Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy. European J Neurol . 2015;22(7):1124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4464987</ArticleId><ArticleId IdType="pubmed">25907824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zung WW. The measurement of affects: depression and anxiety. Mod Probl Pharmacopsychiatry . 1974;7(0):170&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">4153516</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor KM, Davidson JR, Churchill LE. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry . 2000;176:379&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">10827888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandel E. R., Schwartz J. H., Jessell T. M. Principles of Neural Science . Vol. 4. New York: McGraw-Hill; 2000.</Citation></Reference><Reference><Citation>Ryabkova VA, Gavrilova NY, Fedotkina TV. Myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID syndrome: a common neuroimmune ground? Diagnostics (Basel) 2022;13(1):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9818907</ArticleId><ArticleId IdType="pubmed">36611357</ArticleId></ArticleIdList></Reference><Reference><Citation>Petracek LS, Suskauer SJ, Vickers RF. Adolescent and young adult ME/CFS after confirmed or probable COVID-19. Front Med (Lausanne) 2021;8:668944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116546</ArticleId><ArticleId IdType="pubmed">33996867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokorelis C, Malone L, Byrne K. Onset of postural orthostatic tachycardia syndrome (POTS) following COVID-19 infection: a pediatric case report. Clin Pediatr (Phila) 2023;62(2):92&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833997</ArticleId><ArticleId IdType="pubmed">35883258</ArticleId></ArticleIdList></Reference><Reference><Citation>James W. The physical basis of emotion (reprinted from Psychological Review, Vol. 1, p. 516, 1894) Psychological Review . 1994;101(2):205&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8022955</ArticleId></ArticleIdList></Reference><Reference><Citation>Eccles JA, Owens AP, Mathias CJ. Neurovisceral phenotypes in the expression of psychiatric symptoms. Front Neurosci . 2015;9:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4322642</ArticleId><ArticleId IdType="pubmed">25713509</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens AP, Friston KJ, Low DA. Investigating the relationship between cardiac interoception and autonomic cardiac control using a predictive coding framework. Auton Neurosci . 2018;210:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29331491</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J . 2023;61(1):2200970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorchenko Y, Zimba O. Long COVID in autoimmune rheumatic diseases. Rheumatol Int . 2023;43(7):1197&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10061411</ArticleId><ArticleId IdType="pubmed">36995436</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma C, Bayry J. High risk of autoimmune diseases after COVID-19. Nat Rev Rheumatol . 2023;19(7):399&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10096101</ArticleId><ArticleId IdType="pubmed">37046064</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis . 2022;225(12):2155&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol . 2022;23(2):210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Dinnes J, Takwoingi Y. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev . 2020;6(6):CD013652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387103</ArticleId><ArticleId IdType="pubmed">32584464</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A, Lowe N, Arnsten AF. Clinical experience with the &#x3b1;2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in &#x201c;Long-COVID19.&#x201d;. Neuroimmunology Reports . 2023;3:100154.</Citation></Reference><Reference><Citation>Collaco R, Lammens M, Blevins C. Anxiety and dysautonomia symptoms in patients with a Nav1.7 mutation and the potential benefits of low-dose short-acting guanfacine. Clinical Autonomic Research . (Forthcoming)</Citation><ArticleIdList><ArticleId IdType="pubmed">38064009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekins S, Gerlach J, Zorn KM. Repurposing Approved drugs as inhibitors of K(v)7.1 and Na(v)1.8 to treat Pitt Hopkins Syndrome. Pharm Res . 2019;36(9):137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814258</ArticleId><ArticleId IdType="pubmed">31332533</ArticleId></ArticleIdList></Reference><Reference><Citation>Foadi N, Berger C, Pilawski I. Inhibition of voltage-gated Na(+) channels by the synthetic cannabinoid ajulemic acid. Anesth Analg . 2014;118(6):1238&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24755846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghovanloo MR, Shuart NG, Mezeyova J. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem . 2018;293(43):16546&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6204917</ArticleId><ArticleId IdType="pubmed">30219789</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason ER, Cummins TR. Differential inhibition of human Nav1.2 resurgent and persistent sodium currents by cannabidiol and GS967. Int J Mol Sci . 2020;21(7):2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177867</ArticleId><ArticleId IdType="pubmed">32244818</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins AR. Cannabinoid interactions with ion channels and receptors. Channels (Austin) 2019;13(1):162&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527074</ArticleId><ArticleId IdType="pubmed">31088312</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>